Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 110 participants.
Also called NCT07452913
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 110 participants
- Sponsor
- Registry
-
NCT07452913
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Pakistan
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT07452913. Randomized; no masking; primary purpose treatment. Start 2026-01-01 (actual); primary completion 2026-03-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Metformin+ Empagliflozin + Sitagliptin
- Intervention (Drug)
- Metformin + Empagliflozin + Linagliptin
- Lead sponsor
- Bahria University
Record details
- Record id
cardio:ct-nct07452913- Content hash
e11ff5df1aba33390dab5c9a2101f83173c4a3271e935454c29ba8cc09f0e4b3